Hennion & Walsh Asset Management Inc. Grows Stock Position in Indivior PLC (NASDAQ:INDV)

Hennion & Walsh Asset Management Inc. raised its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 48.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 142,444 shares of the company's stock after buying an additional 46,509 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.10% of Indivior worth $1,357,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of INDV. GF Fund Management CO. LTD. acquired a new stake in Indivior in the 4th quarter worth about $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Indivior during the fourth quarter worth $56,000. Lazard Asset Management LLC acquired a new position in shares of Indivior during the fourth quarter worth $57,000. Stifel Financial Corp grew its stake in shares of Indivior by 24.0% during the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock worth $158,000 after purchasing an additional 2,450 shares in the last quarter. Finally, Rathbones Group PLC grew its stake in shares of Indivior by 11.6% during the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock worth $183,000 after purchasing an additional 1,483 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Price Performance

Shares of INDV stock opened at $14.07 on Friday. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $17.09. The firm has a market capitalization of $1.94 billion, a P/E ratio of -40.20 and a beta of 0.66. The company's fifty day moving average price is $10.77 and its two-hundred day moving average price is $10.84.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. On average, sell-side analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.